New drug combo aims to slow diabetic retinopathy
NCT ID NCT07230184
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase 4 trial tested whether adding a second drug (B55R2) to standard treatment (B55R1) works better for people with non-proliferative diabetic retinopathy, an early stage of diabetic eye disease. 52 adults with mild to severe disease took either the combination or B55R1 alone twice daily for 24 weeks. The main goal was to see if hard exudates (fatty deposits in the eye) improved by at least one grade.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- B55R1 and B55R2 (drug combination)
- What this could lead to
- If successful, this combination could offer a better way to reduce hard exudates and control diabetic retinopathy progression.
- What could go wrong
- This is a small, completed Phase 4 trial with only 52 participants. Results may not apply to all patients, and the benefit over existing treatment may be modest.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-PROLIFERATIVE DIABETIC RETINOPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
AJU Pharm Co., Ltd.
Seoul, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New eye drug aims to stop diabetic vision loss
- New eye drug shows promise for diabetic vision loss
- New study aims to catch diabetic eye disease before it steals sight
- Could eye drops replace needles for diabetic eye swelling?
- Could your genes predict blindness from diabetes?
- Common heart drug may shield eyes of type 1 diabetes patients